Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Take-it slow biosimilar approach by US FDA: best for industry?

This article was originally published in SRA

Executive Summary

Even though Congress put in place clear criteria when it wrote the Biologics Price Competition and Innovation Act (BPCIA), the task of actually approving biosimilars in the US has turned out to be much more complicated than lawmakers may have anticipated, according to Kim Greco, director of global regulatory and R&D policy at biotech giant Amgen.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS118305

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel